Variability of drug metabolism, especially that of the most important phase I enzymes or
cytochrome P450 (CYP) enzymes, is an important complicating factor in many areas of …

A key issue in the treatment of many cancers is the development of resistance to
chemotherapeutic drugs. Resistance mechanisms are numerous and complex. One of them …

Interindividual differences of drug response are an important cause of treatment failures and
adverse drug reactions. The identification of polymorphisms explaining distinct phenotypes …

The last decade of research into the pharmacogenetics of antipsychotics has seen the
development of genetic tests to determine the patients' metabolic status and the first attempts …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …

Polymorphic drug-metabolizing enzymes (DMEs) are responsible for the metabolism of the
majority of psychotropic drugs. By explaining a large portion of variability in individual drug …

Phenotyping for drug metabolizing enzymes and transporters is used to assess
quantitatively the effect of an intervention (eg, drug therapy, diet) or a condition (eg, genetic …

Drawing on insights from work in medical history and sociology, this book analyzes
changing meanings of personalized medicine over time, from the rise of biomedicine in the …

Pharmacogenomics is one of the first clinical applications of the postgenomic era. It
promises personalized medicine rather than the established “one size fits all” approach to …

Observations over the later half of the last century have suggested that genetic factors may
be the prime determinant of drug response, at least for some drugs. Retrospectively …